Skip to search formSkip to main contentSkip to account menu

fluticasone / salmeterol

Known as: fluticasone-salmeterol, FLUTICASONE/SALMETEROL, Fluticasone Salmeterol Combination 
National Institutes of Health

Related topics

Related topics

3 relations
Fluticasone Propionate, Salmeterol Xinafoate Drug Combinationfluticasonesalmeterol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners.
BACKGROUND The choice of inhaler device for patients with chronic obstructive pulmonary disease (COPD) depends upon multiple… 
Review
2013
Review
2013
Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children.
BACKGROUND Asthma is characterised by chronic inflammation of the airways and recurrent exacerbations with wheezing, chest… 
Highly Cited
2010
Highly Cited
2010
Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device.
Highly Cited
2008
Highly Cited
2008
Fluticasone Propionate Protects against Ozone-Induced Airway Inflammation and Modified Immune Cell Activation Markers in Healthy Volunteers
Background Ozone exposure induces airway neutrophilia and modifies innate immune monocytic cell-surface phenotypes in healthy… 
Review
2007
Review
2007
Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.
BACKGROUND Long-acting beta-agonists and inhaled corticosteroids have both been recommended in guidelines for the treatment of… 
Highly Cited
2003
Highly Cited
2003
Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.
We evaluated whether montelukast conferred additive effects in patients with asthma receiving fluticasone/salmeterol (FP/SM… 
Highly Cited
2003
Highly Cited
2003
Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction.
Turbuhaler and Salbutamol-Diskus produce therapeutic doses at peak inspiratory flow (PIF) of >30 L/min. However, the optimum flow… 
Highly Cited
1999
Highly Cited
1999
The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma.
Salmeterol xinafoate is an inhaled long-acting beta2-adrenoceptor agonist recently introduced for the treatment of asthma. Both… 
Highly Cited
1996
Highly Cited
1996
Salmeterol tachyphylaxis in steroid treated asthmatic subjects.
BACKGROUND: Tachyphylaxis to the protection afforded by salmeterol to broncho-constrictor stimuli after regular use has been… 
Highly Cited
1995
Highly Cited
1995
Salmeterol xinafoate in children on high dose inhaled steroids.
BACKGROUND Current UK and international guidelines on asthma management recommend that, in pediatric patients still symptomatic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)